with clinically diagnosed mild and stable airway or parenchymal lung disease, or incidental disease detected on imaging, who have moderate-to-high disease activity Studies indicate that preexisting lung disease is a risk factor for methotrexate-related pneumonitis Heart failure Addition of a non-TNF inhibitor bDMARD or tsDMARD is conditionally recommended over addition of a TNF inhibitor for patients with New York Heart Association (NYHA) class III or IV heart failure and an inadequate response to csDMARDs Switching to a non-TNF inhibitor bDMARD or tsDMARD is conditionally recommended over continuation of a TNF inhibitor for patients taking a TNF inhibitor who develop heart failure These recommendations are based on the risk of worsening heart failure observed in randomized clinical trials of TNF inhibitors in patients with NYHA class III or IV heart failure without RA Lymphoproliferative disorder Rituximab is conditionally recommended over other DMARDs for patients who have a